Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cary: a few clarifications, for the benefit of others on here:
1. The company name is actually MPX Bioceutical, not MPS.
2. I also really like MPX's business model, a lot. But there are other companies with similar business models. iAnthus Capital (IAN or ITHUF), Liberty Health Sciences (LHS or LHSIF) and GB Sciences (GBLX) all come to mind. There are others, I'm sure.
The TSX threat should has no material impact on CBICF/BCC, as it is listed on the CNSX and not the TSX or TSXV. The CNSX follows the CSE guidance, which was (Aug 4, 2017):
So, as long as BCC continues to make "appropriate risk disclosure," then it should be fine with respect to maintaining its listed status.
Now, this doesn't mean that that TSX turmoil can't impact the company's stock price. The entire sector seems to drop after these TSX scares, even if the company has no business assets in the US or is not listed on the TSX/TSXV.
Finally, its worth acknowledging that the TSX issues do impact CBICF/BCC in that they will not be able to uplist under the current TSX rules. That limits institutional investment in the near term, until either TSX changes their stance or the US legalizes.